ArticleFrontiers in pharmacology2025
Gastric mucosal repair by Men's Huwei Powder via EGF-NO/PGE2-PI3K-TLR4 in RELISH: Restoring Equilibrium through long-term integration of synergistic health.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Water-responsive injectable hydrogel achieving rapid in situ gelation and long-term colonic mucoadhesion for efficient fecal microbiota transplantation.Bioactive materials · 2027Article
- A review of current evidence and perspectives on the mechanisms and clinical significance of hypoxia-induced remodeling of the gastric microbiota-metabolism axis.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric mucosal injury (GMI) involves inflammation, oxidative stress, and barrier dysfunction. Existing therapies offer limited efficacy with side effects. Men's Huwei Powder (MHWP), a Traditional Chinese Medicine (TCM) formula developed under the RELISH (Restoring Equilibrium through Long-term Integration of Synergistic Health) framework, aims to restore mucosal and systemic equilibrium. Methods: The experiment was grouped using a uniform design, followed by the construction of an ethanol-induced GMI rat model. The effects of MHWP were assessed through histological examination, ELISA, RT-PCR, 16S rRNA sequencing, and LC-MS-based serum fingerprint analysis. Multivariate modeling techniques, including SPRA, PLSR, and pSEM, were utilized to explore the comprehensive regulatory mechanisms of MHWP. Results: MHWP promotes activation of the EGF-NO/PGE2 axis and concurrently suppresses key nodes of the PI3K/Akt/NF-κB signaling pathway, leading to downregulation of pro-inflammatory cytokines-including IL-1β, IL-6, and TNF-α-in both serum and gastric tissue. Beyond its localized effects, MHWP exerts systemic benefits by inhibiting hepatic TLR4, MyD88, and NF-κB expression, thereby reducing liver-derived IL-6 and TNF-α and ameliorating ethanol-induced liver injury. This hepatic protection contributes to improved gastric mucosal healing and systemic inflammatory balance. Gut microbiota profiling identified key genera-such as Conclusion: MHWP exerts multi-targeted effects through integrated modulation of the liver, gut microbiota, and serum metabolites. These findings underscore its potential as a holistic and sustainable TCM-based intervention for GMI, in alignment with the RELISH framework.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.